Title:
COMBINATION THERAPY METHOD USING MDM2 INHIBITOR AND DNA METHYLTRANSFERASE INHIBITOR
Document Type and Number:
WIPO Patent Application WO/2018/074387
Kind Code:
A1
Abstract:
The purpose of the present invention is to provide a medicine or a cancer therapy method each using a combination of a compound having an MDM2 inhibitory activity and a DNA methyltransferase inhibitor.
Provided is a medicine or a combination therapy method each using a combination of (3'R,4'S,5'R)-N-[(3R,6S)-6-carbamoyltetrahydro-2H-pyran-3-yl]-6"-chloro-4'-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2"-oxo-1",2"-dihydrodispiro[cyclohexane-1,2'-pyrrolidine-3',3"-indole]-5'-carboxamide or a pharmaceutically acceptable salt thereof and a DNA methyltransferase inhibitor.
Inventors:
SEKI TAKAHIKO (JP)
Application Number:
PCT/JP2017/037284
Publication Date:
April 26, 2018
Filing Date:
October 16, 2017
Export Citation:
Assignee:
DAIICHI SANKYO CO LTD (JP)
International Classes:
A61K45/00; A61K31/4439; A61K31/706; A61P35/00; A61P35/02; A61P43/00
Domestic Patent References:
| WO2012121361A1 | 2012-09-13 | |||
| WO2016133194A1 | 2016-08-25 | |||
| WO2015070224A2 | 2015-05-14 | |||
| WO2016056673A1 | 2016-04-14 | |||
| WO2006091646A2 | 2006-08-31 | |||
| WO2006136606A2 | 2006-12-28 | |||
| WO2007104664A1 | 2007-09-20 | |||
| WO2007104714A1 | 2007-09-20 | |||
| WO2008034736A2 | 2008-03-27 | |||
| WO2008036168A2 | 2008-03-27 | |||
| WO2008055812A1 | 2008-05-15 | |||
| WO2008141917A1 | 2008-11-27 | |||
| WO2008141975A1 | 2008-11-27 | |||
| WO2009077357A1 | 2009-06-25 | |||
| WO2009080488A1 | 2009-07-02 | |||
| WO2010084097A1 | 2010-07-29 | |||
| WO2010091979A1 | 2010-08-19 | |||
| WO2010094622A1 | 2010-08-26 | |||
| WO2010121995A1 | 2010-10-28 | |||
| WO2008119741A2 | 2008-10-09 | |||
| WO2010031713A1 | 2010-03-25 | |||
| WO2010028862A1 | 2010-03-18 | |||
| WO2006024837A1 | 2006-03-09 | |||
| WO2012121361A1 | 2012-09-13 | |||
| WO2008039218A2 | 2008-04-03 | |||
| WO2013059738A2 | 2013-04-25 |
Other References:
TANG, Y. A. ET AL.: "MDM2 Overexpression Deregulates the Transcriptional Control of RB/E2F Leading to DNA Methyltransferase 3A Overexpression in Lung Cancer", CLIN. CANCER RES., vol. 18, no. 16, 2012, pages 4325 - 4333, XP055593815
J. AM. CHEM. SOC., vol. 127, 2005, pages 10130 - 10131
J. MED. CHEM., vol. 49, 2006, pages 3432 - 3435
J. MED. CHEM., vol. 52, 2009, pages 7970 - 7973
J. MED. CHEM., vol. 49, 2006, pages 6209 - 6221
TRENDS PHARMACOL. SCI., vol. 31, 2010, pages 536 - 546
DRUG DISCOV. TODAY, vol. 16, 2011, pages 418 - 425
CELL. SIGNAL., vol. 23, 2011, pages 1082 - 1093
IUPC, PURE AND APPLIED CHEMISTRY, vol. 68, 1996, pages 2193 - 2222
"Molecule Design", vol. 7, 1990, HIROKAWA-SHOTEN LTD., article "Development of Pharmaceutical Products", pages: 163 - 198
See also references of EP 3527226A4
J. AM. CHEM. SOC., vol. 127, 2005, pages 10130 - 10131
J. MED. CHEM., vol. 49, 2006, pages 3432 - 3435
J. MED. CHEM., vol. 52, 2009, pages 7970 - 7973
J. MED. CHEM., vol. 49, 2006, pages 6209 - 6221
TRENDS PHARMACOL. SCI., vol. 31, 2010, pages 536 - 546
DRUG DISCOV. TODAY, vol. 16, 2011, pages 418 - 425
CELL. SIGNAL., vol. 23, 2011, pages 1082 - 1093
IUPC, PURE AND APPLIED CHEMISTRY, vol. 68, 1996, pages 2193 - 2222
"Molecule Design", vol. 7, 1990, HIROKAWA-SHOTEN LTD., article "Development of Pharmaceutical Products", pages: 163 - 198
See also references of EP 3527226A4
Attorney, Agent or Firm:
ISHIBASHI, Koki et al. (JP)
Download PDF: